Molecular targeted treatment and drug delivery system for gastric cancer

Jiang, Lanxin; Gong, Xiaomin; Liao, Wenjian; Lv, Nonghua; Yan, Runwei

doi:10.1007/s00432-021-03520-x

“…e key of targeted therapy is to find the genes and proteins that play a key role in the development of GC and to intervene against them, so as to achieve the purpose of treatment. At present, the targeted therapy of GC has made a substantial progress [7,8].…”

Section: Introductionmentioning

confidence: 99%

The Effect and Mechanism of lncRNA NR2F1-As1/miR-493-5p/MAP3K2 Axis in the Progression of Gastric Cancer

Liao¹,

Wen

²

,

Luo

³

2021

Journal of Oncology

View full text Add to dashboard Cite

Background. LncRNA NR2F1-AS1 has been identified as an oncogene in some human tumors, such as breast cancer, nonsmall cell lung cancer, and esophageal squamous cell carcinoma. Nonetheless, whether NR2F1-AS1 is involved in the progression of gastric cancer (GC) remains unknown. Methods. The expression patterns of NR2F1-AS1, MAP3K2, and miR-493-5p in GC tissues and cells were detected by RT-qPCR. The protein expression of MAP3K2 was assessed by the Western blotting assay. The MTT assay and flow cytometry were performed to measure cell proliferation and cell apoptosis in GC cells. The transwell assay was adopted to assess cell migration in GC cells. The relationship between NR2F1-AS1, MAP3K2, and miR-493-5p was verified by a dual-luciferase reporter assay. Results. The increased NR2F1-AS1 and MAP3K2 expressions were discovered in GC tissues and cells compared with control groups. Knockdown of NR2F1-AS1 and MAP3K2 dramatically suppressed cell proliferation and migration, while it enhanced cell apoptosis in GC cells. In addition, NR2F1-AS1 was found to be a sponge of miR-493-5p, and MAP3K2 was a downstream gene of miR-493-5p. Moreover, the expression of MAP3K2 was notably reduced by miR-493-5p, and NR2F1-AS1 counteracted the inhibition of miR-493-5p. Conclusion. Thus, NR2F1-AS1 was verified to regulate GC cell progression by sponging miR-493-5p to upregulate MAP3K2 expression.

show abstract

“…In the advanced stage of GC, drug therapy becomes the main means. However, the efficacy of current traditional chemotherapy is limited and the GC patients' median overall survival is low [ 12 ]. So, the analysis of underlying pathogenesis and the research on treatment intervention targets for GC have become the present research hotspot.…”

Section: Discussionmentioning

confidence: 99%

Aberrant Expression TFR1/CD71 in Gastric Cancer Identifies a Novel Potential Prognostic Marker and Therapeutic Target

Cao

¹

,

Hu

²

,

Xu

³

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Background. Gastric cancer (GC) is one of the most common malignant tumors with poor prognosis. So far, other than the HER2, GC lacks effective therapeutic targets. Transferrin receptor 1 (TFR1) expressions are abnormally upregulated in various cancers for the satisfaction of iron demand increased. This study aimed to explore the expression and clinical value of TFR1 in GC. Methods. A tissue microarray including GC tissues and matched noncancerous tissues from 155 GC patients were collected. Moreover, the level of TFR1 expression was detected by immunohistochemistry, and we also evaluated the relationship between TFR1 expression and the clinicopathologic characteristics. What is more, univariate analysis and multivariate analysis were used to evaluate the risk factors and independent risk factors affecting the prognosis of GC. Results. We found that TFR1 was overexpressed in GC tissues compared with noncancerous tissues, and a significant relationship was found between TFR1 expression and age ( P = 0.001 ), Lauren type ( P = 0.008 ), T stage ( P = 0.003 ), HER2 ( P = 0.003 ), PD-L1 ( P < 0.001 ), and the level of CA72-4 ( P = 0.028 ). Survival analysis confirmed that GC patients with positive TFR1 expression had a poorer OS than that with negative TFR1 expression, and TFR1 expression was an independent risk factor in GC. Furthermore, we also found that there was a significant difference between the TFR1-PD-L1− group and the TFR1+PD-L1+ group ( P = 0.023 ), while there was no significant difference between the TFR1-PD-L1− group and the TFR1+PD-L1− group ( P = 0.119 ), or between the TFR1-PD-L1− group and the TFR1-PD-L1+ group ( P = 0.396 ). Conclusions. TFR1 was overexpressed in GC and its aberrant expression identifies a novel potential prognostic marker and therapeutic target. In addition, TFR1 expression may be associated with the immune microenvironment and suppress the immune response via regulating the PD-L1 expression.

show abstract

“…Meanwhile, reduced drug accumulation at normal organs can reduce the damage to adjacent normal tissues. In addition, drug delivery systems also have good biocompatibility and biodegradability [ 120 , 121 , 122 , 123 , 124 ]. Therefore, in recent years, researchers have developed many nanostructures such as hydrogels, liposomes, cell membranes, and micelles as drug delivery systems in cancer treatment to improve the treatment effect and reduce side effects.…”

Section: Drug Delivery Systemmentioning

confidence: 99%

Progress of Nanomaterials-Based Photothermal Therapy for Oral Squamous Cell Carcinoma

Qin

¹

,

Sun

²

,

Bai

³

et al. 2022

IJMS

View full text Add to dashboard Cite

Oral squamous cell carcinoma (OSCC) is one of the top 15 most prevalent cancers worldwide. However, the current treatment models for OSCC (e.g., surgery, chemotherapy, radiotherapy, and combination therapy) present several limitations: damage to adjacent healthy tissue, possible recurrence, low efficiency, and severe side effects. In this context, nanomaterial-based photothermal therapy (PTT) has attracted extensive research attention. This paper reviews the latest progress in the application of biological nanomaterials for PTT in OSCC. We divide photothermal nanomaterials into four categories (noble metal nanomaterials, carbon-based nanomaterials, metal compounds, and organic nanomaterials) and introduce each category in detail. We also mention in detail the drug delivery systems for PTT of OSCC and briefly summarize the applications of hydrogels, liposomes, and micelles. Finally, we note the challenges faced by the clinical application of PTT nanomaterials and the possibility of further improvement, providing direction for the future research of PTT in OSCC treatment.

show abstract

Molecular targeted treatment and drug delivery system for gastric cancer

Cited by 21 publications

References 146 publications

The Effect and Mechanism of lncRNA NR2F1-As1/miR-493-5p/MAP3K2 Axis in the Progression of Gastric Cancer

The Effect and Mechanism of lncRNA NR2F1-As1/miR-493-5p/MAP3K2 Axis in the Progression of Gastric Cancer

Aberrant Expression TFR1/CD71 in Gastric Cancer Identifies a Novel Potential Prognostic Marker and Therapeutic Target

Progress of Nanomaterials-Based Photothermal Therapy for Oral Squamous Cell Carcinoma

Contact Info

Product

Resources

About